Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Fangfei Qian"'
Autor:
Yanwei Zhang, Beibei Sun, Yinghong Yu, Jun Lu, Yuqing Lou, Fangfei Qian, Tianxiang Chen, Li Zhang, Jiancheng Yang, Hua Zhong, Ligang Wu, Baohui Han
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract This research explores the potential of multimodal fusion for the differential diagnosis of early-stage lung adenocarcinoma (LUAD) (tumor sizes < 2 cm). It combines liquid biopsy biomarkers, specifically extracellular vesicle long RNA (evlRN
Externí odkaz:
https://doaj.org/article/4c9b857922374136bc2311cb7ee08835
Autor:
Yujing Li, Yanan Wang, Wensheng Zhou, Ya Chen, Yuqing Lou, Fangfei Qian, Jun Lu, Haohua Jiang, Biao Xiang, Yanwei Zhang, Baohui Han, Wei Zhang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 19, Pp 2711-2722 (2022)
Abstract Background Small cell lung cancer (SCLC) is the most malignant and common form of neuroendocrine lung cancer with pure (P‐SCLC) and combined subtypes (C‐SCLC). However, little is known about the differences between these two groups and i
Externí odkaz:
https://doaj.org/article/2498bc8738a34a6194154ec18d87c4de
Autor:
Yujing Li, Haohua Jiang, Fangfei Qian, Ya Chen, Wensheng Zhou, Yanwei Zhang, Jun Lu, Yuqing Lou, Baohui Han, Wei Zhang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionPlatinum-based chemotherapy is still the standard of care for Epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) patients after developing EGFR-TKI resistance. However, no study focusing on the role of immu
Externí odkaz:
https://doaj.org/article/f387a4eefc4948298b3ae95cb1a2c201
Autor:
Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Jun Lu, Yanwei Zhang, Fangfei Qian, Bo Zhang, Shuyuan Wang, Kai Wang, Wei Zhang, Baohui Han
Publikováno v:
Thoracic Cancer, Vol 13, Iss 5, Pp 732-741 (2022)
Abstract Background Local consolidative therapy (LCT) has emerged as a treatment option in patients with oligometastatic non‐small cell lung cancer (NSCLC) undergoing chemotherapy or targeted therapy. However, the current literature lacks evidence
Externí odkaz:
https://doaj.org/article/85bc7db3a81442c8be37ec3b3816db00
Autor:
Wensheng Zhou, Zhichao Liu, Yanan Wang, Yanwei Zhang, Fangfei Qian, Jun Lu, Huimin Wang, Ping Gu, Minjuan Hu, Ya Chen, Zhengyu Yang, Ruiying Zhao, Yuqing Lou, Baohui Han, Wei Zhang
Publikováno v:
Cancer Medicine, Vol 11, Iss 5, Pp 1299-1309 (2022)
Abstract Background Epidermal growth factor receptor (EGFR) mutations were frequently found with concomitant genetic alterations in lung adenocarcinoma (LUAD). This study aimed to investigate the profile of concomitant alterations of EGFR‐mutant LU
Externí odkaz:
https://doaj.org/article/86bb4cdce91149b19e9649a23307fcc2
Autor:
Wei Zhang, Yanwei Zhang, Wensheng Zhou, Fangfei Qian, Minjuan Hu, Ya Chen, Jun Lu, Yuqing Lou, Baohui Han
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Angiogenic placental growth factor (PlGF) plays a role in hypoxia-induced angiogenesis. Here, we aimed to investigate the biological roles of PlGF in cell proliferation and glycolysis of lung adenocarcinoma (LUAD) and the underlyi
Externí odkaz:
https://doaj.org/article/b25372a6674b41c588796793f774fac1
Autor:
Zhengyu Yang, Ya Chen, Yanan Wang, Minjuan Hu, Fangfei Qian, Yanwei Zhang, Bo Zhang, Wei Zhang, Baohui Han
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
ObjectiveSeveral trials have shown that pembrolizumab plus chemotherapy was more effective in patients with advanced non-small-cell lung cancer (NSCLC) than chemotherapy monotherapy. However, whether pembrolizumab plus chemotherapy is still a better
Externí odkaz:
https://doaj.org/article/1c8f063ec58340a992e6a9dc7efef8e2
Autor:
Yanan Wang, Fangfei Qian, Ya Chen, Zhengyu Yang, Minjuan Hu, Jun Lu, Yanwei Zhang, Wei Zhang, Lei Cheng, Baohui Han
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesPulmonary large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC) are both classified as pure and combined subtypes. Due to the low incidence and difficult diagnosis of combined LCNEC (C-LCNEC) and combined SCLC (C-SCL
Externí odkaz:
https://doaj.org/article/03000916ddde471487d1c6ad2edaa4ed
Autor:
Ya Chen, Yanan Wang, Zhengyu Yang, Minjuan Hu, Yanwei Zhang, Fangfei Qian, Wei Zhang, Bo Zhang, Baohui Han
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesPembrolizumab plus platinum-based chemotherapy and pembrolizumab monotherapy (PM) both become standard of care in patients with advanced non-small-cell lung cancer (NSCLC) and a programmed death ligand 1 (PD-L1) tumor proportion score (TPS)
Externí odkaz:
https://doaj.org/article/4dd7e888f4b44caf8127ffdb937fe4e2
Autor:
Ya Chen, Zhengyu Yang, Yanan Wang, Minjuan Hu, Bo Zhang, Yanwei Zhang, Fangfei Qian, Wei Zhang, Baohui Han
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesMore and more encouraging evidence revealed that immunotherapy could improve clinical outcomes in patients with previously treated non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) variations. However, immunoth
Externí odkaz:
https://doaj.org/article/999f817365854bafbf6963a3324a0d43